alt-801
Recombinant proteinexperimental
Clinical trial activity
12 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00496860)
Timeline
Indications
Studied for
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Diabetes Mellitus, Type 2 · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Melanoma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1
- Non-alcoholic Fatty Liver Disease · Phase 1
- Obesity · Phase 2
- Ureteral Neoplasms · Phase 1/Phase 2
- Urethral Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
- Cellular tumor antigen p53INHIBITOR
TP53 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- IL2
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297689 ↗
Also known as
- alt-801
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05295875 | Phase 2 | Mar 31, 2022 | Altimmune, Inc. |
| NCT05292911 | Phase 1 | Mar 9, 2022 | Altimmune, Inc. |
| NCT05134662 | Phase 1 | Jan 31, 2022 | Altimmune, Inc. |
| NCT04972396 | Phase 1 | Oct 5, 2021 | Altimmune, Inc. |
| NCT05006885 | Phase 1 | Sep 30, 2021 | Altimmune, Inc. |
| NCT04561245 | Phase 1 | Nov 30, 2020 | Altimmune, Inc. |
| NCT01670994 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2012 | Altor Bioscience, National Cancer Institute (NCI) |
| NCT01625260 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2012 | Altor Bioscience, James and Esther King Biomedical Research Program |
| NCT01478074 | Phase 1 | Nov 1, 2011 | Altor Bioscience, University of Texas at Houston |
| NCT01326871 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2011 | Altor Bioscience, National Cancer Institute (NCI) |
| NCT01029873 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2010 | Altor Bioscience, National Cancer Institute (NCI) |
| NCT00496860 | Phase 1 | May 1, 2007 | Altor Bioscience |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Altimmune, Inc. | For profit | 6 | 6 | 2 | 2020 |
| Altor Bioscience | For profit | 6 | 6 | 2 | 2007 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 1 | 2010 |
| James and Esther King Biomedical Research Program | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1